OncoFusion Leadership

OncoFusion’s founders are endowed professors at the University of Michigan Medical School with many publications in leading journals. They also have successful experience starting up companies based on technologies originated from their labs.

The entire management team is comprised of well-recognized leaders in the biopharmaceutical industry. Meet our leadership team  


Targeting Cancer at the Gene Level

OncoFusion Therapeutics, Inc. (Ann Arbor, MI) is an oncology discovery and development company targeting gene fusions that are thought to drive many common cancers.

The technology is based on discoveries from the laboratories of the companies’ co-founders, Dr. Arul Chinnaiyan and Dr. Shaomeng Wang, at the University of Michigan.



Latest News

OncoFusion Therapeutics Reacquires Rights to BET Bromodomain Inhibitors

ANN ARBOR, MI — (January 15, 2016) – OncoFusion Therapeutics, Inc. announced today that it has reached an agreement with Medivation, Inc. to reacquire the rights to certain compounds targeting... continue

Oncofusion Enters Into License Agreement with Medivation for Compounds Targeting Bromodomain Proteins

San Francisco, CA and Ann Arbor, MI –  April 23, 2014 – Medivation, Inc. (Nasdaq: MDVN) and OncoFusion Therapeutics, Inc., today announced that they have entered into a research and... continue